PI Industries earnings miss offsets USD 1.2 billion CSM order book recovery

Investment View and Valuation

Motilal Oswal Financial Services Ltd. retained its Buy rating on PI Industries in its August 12, 2026 1QFY27 results update, despite a weak quarter and reductions to its earnings forecasts. The broker remains cautiously optimistic, supported by a stable CSM order book of approximately USD 1.2 billion, a pipeline of new products and potential medium-term growth from biologicals, pharma CRDMO and electronic chemicals.

The target price is Rs 3,000, based on 34 times FY28E EPS. This represents an approximately 9 per cent discount to PI Industries' six-year historical price-to-earnings multiple of 37 times.

1QFY27 Financial Performance

PI Industries reported 1QFY27 revenue of Rs 17,023 million, down 10 per cent year on year and below Motilal Oswal's estimate of Rs 18,325 million. Agrochemical revenue declined 10 per cent to Rs 16,481 million, while pharma revenue fell 25 per cent to Rs 542 million because of order phasing and customer delivery scheduling.

The CSM business declined 13 per cent amid muted global agrochemical demand and continued pricing pressure. Export agrochemical revenue fell 12 per cent and volumes declined 8 per cent. Domestic volumes grew approximately 12 per cent, supported by biologicals, but pricing pressure and delayed-monsoon-led demand deferral limited domestic agri revenue growth to 3 per cent.

Operating performance missed the broker's expectations. EBITDA was 24 per cent below the estimate, while EBITDA margin contracted to 21.6 per cent from the broker's estimate of 26.5 per cent, reflecting lower volumes and adverse operating leverage. Gross margin declined 70 basis points to 56.7 per cent, employee cost rose 310 basis points to 15.3 per cent of sales and other expenses increased 190 basis points to 19.8 per cent.

Agrochemical EBIT margin fell 770 basis points to 23.3 per cent. Pharma recorded an operating loss of Rs 816 million versus a Rs 760 million loss in 1QFY26. Adjusted PAT declined 39 per cent year on year to Rs 2,442 million, below the Rs 3,562 million estimate. Net working capital improved by 19 days sequentially to 120 days, while surplus cash net of debt stood at Rs 8,000 million.

Management Outlook and Growth Drivers

Management guided for low single-digit FY27 revenue growth, expecting an export recovery in 2HFY27 alongside product launches and the scaling of biologicals and pharma. It expects FY27 EBITDA margin to be around 24 per cent and intends to sustain R&D expenditure at 3-4 per cent of revenue.

• New products accounted for 16-18 per cent of CSM revenue in 1QFY27.
• PI Industries has around 60 active projects and plans four to five FY27 launches, including the proprietary diamide insecticide Pi-Liprole.
• Management said delayed pharma projects reflect customer timing rather than lost business.
• The company is building an integrated discovery-to-commercialisation CRDMO platform through Integrated Drug Discovery partnerships.

Biologicals, Electronic Chemicals and Capex

The biological nematicide platform is being developed through more than 500 field trials and more than 1,000 grower engagements globally. Management views current biologicals losses as investments needed to build the platform.

Electronic chemicals are a longer-gestation diversification opportunity, although commercial-scale manufacturing and supplies have commenced. PI Industries commissioned an advanced flow chemistry facility during the quarter and guided for FY27 capex of Rs 7,000-8,000 million across manufacturing, innovation, electronic chemicals, biologicals and pharma.

Earnings Forecast Revisions

Motilal Oswal cut its FY27E and FY28E forecasts following the weak quarter. Revenue estimates were reduced by 6 per cent each, EBITDA estimates by 12 per cent and 10 per cent, respectively, and PAT estimates by 15 per cent and 12 per cent, respectively.

The broker forecasts FY26-28 revenue, EBITDA and adjusted PAT CAGR of 7 per cent, 8 per cent and 4 per cent, respectively.

Key Risks to the Thesis

• A prolonged global crop-protection downturn and weak crop economics.
• Channel inventory and continued pricing pressure.
• Geopolitical disruptions, tariffs and supply-chain costs.
• Pharma revenue timing, as delayed projects could defer the expected growth contribution.
• Ongoing biologicals investment and the long gestation period for electronic chemicals.